Our innovative approach
The main objective of our histiocytosis research program is to improve the understanding and treatment of Langerhans cell histiocytosis and hemagophagocytic lymphohistiocytosis. We participate in internal research initiatives as well as those directed by the Histiocyte Society, an international research collaboration.
Dana-Farber/Children's Hospital Cancer Center is a world leader in opening new avenues of "translational research," bringing laboratory advances to the bedside and doctor's office as quickly as possible. All of our senior medical staff members of the Histiocytosis Program participate in clinical research activities.
Following are some of the research initiatives under way in our research program:
- The program treats patients in accordance with protocols established by the Histiocyte Society. Children with LCH and HLH have the opportunity to take part in clinical trials organized by the Histiocyte Society.
- We established a clinical database to identify patterns of disease in patients with LCH and to determine the effectiveness of specific treatments.
- Our clinical database has helped us identify a unique genetic mutation associated with histiocytosis. We are working to develop new treatments based on this discovery.
- In collaboration with Dana-Farber Cancer Institute, we are evaluating the biology of histiocytic disorders. If your child has biopsies of histiocytic lesions, you may be offered the chance to participate in a study that uses tissue samples to learn more about the condition.
- Our researchers are working to develop reduced intensity treatment strategies that will have fewer short-term and long-term side effects.
The Histiocyte Society is a nonprofit, international group of more than 200 physicians and scientists who are committed to improving the lives of patients with histiocytosis by conducting clinical and laboratory research into the causes and treatment of this disease. This society provides a forum for the exchange of information and a framework for organized activities.
The Histiocyte Society also releases treatment guidelines for LCH and HCH. Children treated through our Histiocytosis Program have the opportunity to participate in innovative clinical trials organized by the Histiocyte Society.
Carlos Rodriguez-Galindo, MD, director of the Bone and Soft Tissue Program at Dana-Farber/Children's Hospital Cancer Center, serves on the Executive Board of the Histiocyte Society and is co-chair of the Histiocyte Society’s Langerhans Histiocytosis IV Study Group.
For more information about the Histiocyte Society, please contact Barbara Degar, MD, at 617-632-5508.